Hovione and Zerion Pharma collaborate to commercialise low drug solubility solution

By joining forces, the two companies will be able to bring Dispersome to the market faster for novel drug development

The solution is Dispersome — Zerion´s proprietary solubility enhancement technology platform, which is reported to greatly enhance the solubility of poorly soluble, oral drugs and improve bioavailability.

The technology uses natural protein-based excipients (beta-lactoglobulin — a sustainable and biodegradable by-product from cheese production) to formulate active pharmaceutical ingredients into amorphous solid dispersions by spray drying.

By combining this technology with its spray drying capabilities, experience in development, scale-up and GMP manufacturing, Hovione further strengthens its position in amorphous solid dispersions.

Accoring to Zerion´s CEO, Ole Wiborg, the partnership will provide them and its pharma partners with "immediate access to the highest quality in upscaling and commercial GMP manufacturing".